For progressing desmoid tumors. Sold as Ogsiveo. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Nirogacestat Hydrobromide (sold as Ogsiveo), first approved Nov 27, 2023, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Ogsiveo | Part D | $35.1M | +75% | 222 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by SurgeryDesmoid Fibromatosis, Recurrent Desmoid Fibromatosis · Children's Oncology Group | Phase 2 | Active, not recruiting | Dec 11, 2019 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Nov 27, 2023 | OgsiveoNDA 217677 · New molecular entity | Springworks | 4 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA